Nanomix, an American developer of mobile, affordable, point-of-care diagnostics, has recently announced that it has entered into a distribution agreement with Bioasia, a Singapore-based medical diagnostics distributor, which will allow Bioasia to market and distribute the Nanōmix eLab® system in Singapore and Brunei, including the Nanōmix S1 Panel assay and future new test products for the eLab system. The system is a mobile, hand-held immunoassay and chemistry diagnostic system used for rapid point-of-care testing while offering a variety of benefits, including results in minutes, lower cost, portability, and quantitative results comparable in quality to those provided by central lab testing.
The system is expected to be able to diagnose critical infections such as sepsis, recognized as a global health crisis with approximately 11 million deaths annually, in as little as 12 minutes, as compared to current diagnostics solutions which may require hours to provide a test result. The he S1 Panel assay has received the CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency (MHRA) registration.
(Sources: Healthcare IT News)